Synaps Dx

Synaps Dx, founded with a mission to advance the diagnosis of neurodegenerative disorders, focuses primarily on Alzheimer's Disease. The company is dedicated to providing healthcare professionals with accurate scientific data to distinguish Alzheimer's from other dementias. Their flagship product, DISCERN™, is a diagnostic tool designed to enhance the early detection and differentiation of Alzheimer's Disease, aiming to improve patient outcomes and reduce uncertainty in diagnosis.

Notable affiliates include leading researchers and clinicians in the field of neurodegenerative diseases. Synaps Dx has garnered attention for its innovative approach and has secured investments from prominent venture capital firms specializing in healthcare technology. The company’s key achievements include significant advancements in diagnostic accuracy and the successful commercialization of DISCERN™. Overall, Synaps Dx has made a substantial impact on the early detection and management of Alzheimer's Disease, contributing to better patient care and advancing the field of neurodegenerative diagnostics.